Bristol-Myers promotes Caforio to COO; Amgen recruits CFO from 3M;

@FiercePharma: Top-read special report Monday: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion. | Follow @TracyStaton

@EricPFierce: New FDA warning letter says Alabama compounder is making sterile drugs in unsanitary facility. More | Follow @EricPFierce

@CarlyHFierce: Allergan spurns Valeant again, but shareholders may have other ideas. Article | Follow @CarlyHFierce

@JustinHFierce: After 7mil US pig deaths from PEDv, Tokyo announces outbreak guidelines on concerns of health-conscious Chinese. Story | Follow @JustinHFierce

> Bristol-Myers Squibb ($BMY) promoted Giovanni Caforio to chief operating officer; he'll add manufacturing and supply-chain duties to his previous role as chief commercial officer. Release

> Amgen ($AMGN) tapped David W. Meline to be SVP and chief financial officer; previously, Meline served in the same roles at 3M Company. Release

> Mylan ($MYL) launched its version of Bristol-Myers Squibb's ($BMY) chemotherapy drug Paraplatin, a treatment for ovarian cancer. Report

> A former SVP at Merck ($MRK) has joined the drug developer Seres as CEO and chairman. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Devicemakers like $MDT, $ABT and $JNJ hold a total of $95 billion offshore--and that's just the tip of the iceberg. Article | Follow @FierceMedDev

@VarunSaxena2: This just in: $MDT will not pursue shareholder complaints against officers, board of directors over Infuse marketing. Filings | Follow @VarunSaxena2

@MichaelGFierce: Mayo Clinic team successfully delivers small molecules to the brain past blood-brain barrier. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: "Hackathons" bring together med tech minds to brainstorm innovative solutions to unmet needs in developing countries. Story from Wired | Follow @EmilyWFierce

> FDA approves Auxogyn embryo test for IVF procedures. Story

> Massachusetts startup develops iOS app for autism. Article

Biotech News

@FierceBiotech: Can Orexigen and its partner Takeda escape the weight-drug jinx? Editor's corner | Follow @FierceBiotech

@JohnCFierce: Still trending: Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide. Article | Follow @JohnCFierce

@DamianFierce: Theme in $AGN's new slides: $VRX's big rush to do a deal is wild suspicious. More | Follow @DamianFierce

@EmilyMFierce: Compound could delay onset of Type 2 diabetes. FierceBiotech Research story | Follow @EmilyMFierce

> Allergan says no to $53B as Valeant gets hostile. Item

> Receptos shares spike as oral drug reduces brain lesions in PhII MS trial. More

> Dutch biotech arGEN-X plots an IPO as it pads its list of partners. Report

> Analysis: Idenix bidding was competitive, driving up the deal value for an eager Merck. Article

Pharma Manufacturing News

> FDA says compounder making drugs under unsanitary conditions. More

> Drugmaker will use MIT 3-D printing process to make fast-melting capsules. Item

> More consolidation in the API market as Provence picks up peptidemaker Synprosis. Report

> Illinois man pleads guilty to selling $3M worth of foreign Botox. Story

> Roche's Avastin and MabThera are added to list of those stolen in Italy. Article

> Dr. Reddy's avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production. More

Biotech Research News

> Compound could delay onset of Type 2 diabetes. Story

> ImStem therapy reverses multiple sclerosis symptoms in mice. More

> Levels of small molecule in brain may indicate depression. Article

> Report: $4.5B needed for BRAIN project through 2025. Item

> Stem cells transplanted successfully in pigs. Story

And Finally... Reset your body clock? Researchers want to test drugs that could make that possible. Report